NCT04762979: An ongoing trial by Marina N Sharifi
This trial is ongoing. It must report results 6 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04762979 |
|---|---|
| Title | A Phase II, Single Arm, Non-randomized Study of Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 12, 2021 |
| Completion date | Oct. 23, 2025 |
| Required reporting date | Oct. 23, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |